Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism

Mayur K. Ladumor, Deepak Kumar Bhatt, Andrea Gaedigk, Sheena Sharma, Aarzoo Thakur, Robin E. Pearce, J. Steven Leeder, Michael B. Bolger, Saranjit Singh, and Bhagwat Prasad

Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Mohali, Punjab, India (M.K.L., S.Sh., A.T., S.Si.); Department of Pharmaceutics, University of Washington, Seattle, Washington (D.K.B., B.P.); Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Department of Pediatrics, Children’s Mercy Kansas City, Kansas City, Missouri (A.G., R.E.P., J.S.L.); School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri (A.G., R.E.P., J.S.L.); and Simulations Plus, Inc., Lancaster, California (M.B.B.)

Received January 19, 2019; accepted May 9, 2019

ABSTRACT

Cytosolic sulfotransferases (SULTs), including SULT1A, SULT1B, SULT1E, and SULT2A isoforms, play noteworthy roles in xenobiotic and endobiotic metabolism. We quantified the protein abundances of SULT1A1, SULT1A3, SULT1B1, and SULT2A1 in human liver cytosol samples (n = 194) by liquid chromatography–tandem mass spectrometry proteomics. The data were analyzed for their associations by age, sex, genotype, and ethnicity of the donors. SULT1A1, SULT1B1, and SULT2A1 showed significant age-dependent protein abundance, whereas SULT1A3 was invariable across 0–70 years. The respective mean abundances of SULT1A1, SULT1B1, and SULT2A1 in neonatal samples was 24%, 19%, and 38% of the adult levels. Interestingly, unlike UDP-glucuronosyltransferases and cytochrome P450 enzymes, SULT1A1 and SULT2A1 showed the highest abundance during early childhood (1 to <6 years), which gradually decreased by approx. 40% in adolescents and adults. SULT1A3 and SULT1B1 abundances were significantly lower in African Americans compared with Caucasians. Multiple linear regression analysis further confirmed the association of SULT abundances by age, ethnicity, and genotype. To demonstrate clinical application of the characteristic SULT ontogeny profiles, we developed and validated a proteomics-informed physiologically based pharmacokinetic model of acetaminophen. The latter confirmed the higher fractional contribution of sulfation over glucuronidation in the metabolism of acetaminophen in children. The study thus highlights that the ontogeny-based age-dependent fractional contribution (fm) of individual drug-metabolizing enzymes has better potential in prediction of drug-drug interactions and the effect of genetic polymorphisms in the pediatric population.

Introduction

The human cytosolic sulfotransferases (SULTs) are important phase II drug-metabolizing enzymes (DMEs) that catalyze sulfate conjugation by transferring a sulfonate (SO3) group from 3′-phosphoadenosine-5′-phosphosulfate to the hydroxyl or amino group of xenobiotic or endobiotic substrates. Several SULT isoforms, i.e., SULT1A1, SULT1A3, SULT1B1, SULT1E1, and SULT2A1, play important roles in the metabolism of drugs, environmental toxins, and endogenous steroids. For example, SULT1A1 is involved in the biotransformation of acetaminophen, minoxidil, 4-hydroxytamoxifen, oxymorphone, nalbuphine, nalorephine, naltrexone, isoflavones, estradiol, and iodothyronines (Coughtrie et al., 1994; Nishiyama et al., 2002; Nowell and Falany, 2006; Kurogi et al., 2014; Marto et al., 2017). Likewise, SULT1A3 is known to metabolize catecholamines, serotonin, salbutamol, ritodrine, and troglitazone (Eisenhofer et al., 1999; Honma et al., 2002; Hui and Liu, 2015; Bairam et al., 2018); SULT1B1 plays a role in elimination of idoxothyrines, thyroxine, and 1-naphthol (Fujita et al., 1997; Wang et al., 1998; Gamage et al., 2006); SULT1E1 metabolizes raloxifene and estrogens (Falany et al., 1995; Schrag et al., 2004, 2006; Cubitt et al., 2011); and SULT2A1 assists in metabolism of ciprofloxacin, desipramine, metoclopramide, dehydroepiandrosterone (DHEA), several bile acids, and 25-hydroxyvitamin D3 (Falany et al., 1994; Meloche et al., 2002, 2004; Cook et al., 2009; Nakamura et al., 2009; Sengunprai et al., 2009; Huang et al., 2010; Wong et al., 2018). Because several of these substrates are

ABBREVIATIONS: Amax, predicted total amount of metabolites eliminated in urine; AUC, area under the plasma concentration-time curve; Cmax, maximum plasma concentration; CNV, copy number variation; DDIs, drug-drug interactions; DHEA, dehydroepiandrosterone; DMEs, drug-metabolizing enzymes; fm, fractional metabolism by individual enzymes; JT, Jonckheere-Terpstra; PBPK, physiologically based pharmacokinetic; PCA, principal component analysis; PK, pharmacokinetics; %CV, percent coefficient of variation; SNPs, single-nucleotide polymorphisms; SULTs, human cytosolic sulfotransferases; UGTs, UDP-glucuronosyltransferases.
relevant to children, it is important to characterize age-dependent abundances of these enzymes.

Unlike cytochrome P450 enzymes (CYPs), phase II drug-metabolism pathways are not well characterized for age-dependent activity and expression owing to the nonavailability of probe substrates, specific inhibitors, and antibodies. Recently, we performed selective quantitative proteomics analysis of UDP-glucuronosyltransferases (UGTs) in human liver samples from 137 pediatric and 37 adult samples, in which we observed distinct patterns of ontogeny for various UGTs (Bhatt et al., 2018, 2019). For example, UGT2B17 expression was rarely observed in children of age <9 years, whereas it sharply increased during teenage years. We also observed that UGT1A1 and UGT2B15 were the major neonatal UGTs, whereas UGT1A4 and UGT2B7 were the major adult isoforms. These ontogeny data were used by us to explain age-dependent pharmacokinetics (PK) of UGT substrates in children (Bhatt et al., 2019).

Some reports in literature indicate that the activity of SULTs is higher than that of UGTs in children, and the phenomenon reverses in adults. For example, acetaminophen glucuronide–to–sulfate metabolite ratio is reported to increase from 0.34 in newborns to 0.75 in children 3–9 years of age, compared with 1.80 in adults (Miller et al., 1976; Behm et al., 2003).

Such nonmonotonic development profiles of DMEs pose a challenge for predicting the fractional metabolism by individual enzymes (f_m) for a given population, e.g., children versus adults. The parameter f_m indicates clinical significance of a drug-metabolism pathway, i.e., a drug with high f_m for a particular DME can display more drug-drug interactions (DDIs) and more pronounced in vivo variability owing to genetic polymorphism (Salem et al., 2013; Prasad and Unadkat, 2015; Umehara et al., 2017). Because f_m is proportional to the relative abundances of DMEs, variable developmental trajectories for individual enzymes may lead to differential f_m with age, eventually resulting in differential metabolic pathways.

Interestingly, several drugs are metabolized by CYPs, UGTs, and SULTs. However, data are sparse on SULT activity in children, and the age-dependent abundance of individual SULT isoforms is not well characterized. Our present study was targeted to fill this important knowledge gap by investigating protein abundances of SULT1A1, SULT1A3, SULT1B1, and SULT2A1 by a robust liquid chromatography–tandem mass spectrometry (LC-MS/MS) proteomics methodology (Bhatt and Prasad, 2018). We made use of cytosolic fractions prepared from the same human livers for which UGT ontogeny data had been reported by us earlier (Bhatt et al., 2019).

To demonstrate additionally the utility of the SULT ontology data generated in this study, we developed a proteomics-informed physiologically based pharmacokinetic (PBPK) model of acetaminophen for predicting age-dependent metabolic switching in its elimination. In adult human liver, acetaminophen is mainly metabolized by conjugation through glucuronidation (52%–57% by UGT1A1, UGT1A6, UGT1A9, and UGT2B15), with sulfation next in importance (30%–44% by SULT1A1, SULT1A3, SULT1E1, and SULT2A1), and a minor contribution by oxidation (5%–10% by CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) (Prescott, 1983; Clements et al., 1984; Critchley et al., 1986, 2005). A PBPK model was reported in the literature to describe acetaminophen PK in children, including neonates and infants (Jiang et al., 2013). However, because selective ontogeny data were not available for the UGTs and SULTs, the reported model used few assumptions regarding DME ontogeny. To address this knowledge deficit, we used the ontogeny data of UGTs (Bhatt et al., 2019), SULTs (described here), and CYPs (unpublished data) to develop and validate a refined acetaminophen pediatric PBPK model.

Materials and Methods

Chemicals and Reagents. Iodoacetamide, dithiothreitol, mass spectrometry-grade trypsin, bovine serum albumin, and synthetic heavy labeled peptides were purchased from Thermo Fisher Scientific (Rockford, IL). Purified SULT1A1 and SULT2A1 protein standards were procured from Abnova (Walnut, CA). Chloroform, ethyl ether, MS-grade acetonitrile (99.9% purity), methanol (>99.5% purity), formic acid (>99.5% purity), and ammonium bicarbonate (98% purity) were purchased from Fisher Scientific (Fair Lawn, NJ).

Human Liver Cytosol Samples. One hundred, ninety-four human liver samples (137 pediatric and 57 adults), a majority of which were previously used by our group to determine abundances of UGTs (Bhatt et al., 2019), carboxylesterases (Boberg et al., 2017), and aldehyde and alcohol dehydrogenases (Bhatt et al., 2017), were used in this study. Detailed donor demographic information on these samples was reported in the aforementioned studies. Of the 137 pediatric liver samples, 129 were provided by Children’s Mercy Kansas City (Kansas City, MO), which were originally procured from various sources, including the National Institute of Child Health and Human Development (NICHD) Brain and Tissue Bank for Developmental Disorders at the University of Maryland (Baltimore, MD); Liver Tissue Cell Distribution System at the University of Minnesota (Minneapolis, MN); University of Pittsburgh (Pittsburgh, PA); Vitron (Tucson, AZ); and Xenotech LLC (Lenexa, KS). The remaining 8 pediatric and 57 adult human liver samples were obtained from the University of Washington School of Pharmacy (Seattle, WA) liver bank. The use of these samples was approved and determined as nonhuman subject research by the institutional review boards of the Children’s Mercy Kansas City and the University of Washington. Information regarding the procurement and storage of these liver samples is described in previous reports (Prasad et al., 2016; Shirasaka et al., 2016; Boberg et al., 2017). The samples were categorized into following groups based on age, sex, and ethnicity: 1) Age: neonatal (0–27 days; n = 4), infancy (28–364 days; n = 17), toddler/early childhood (1 to <6 years; n = 30), middle childhood (6 to <12 years; n = 38), adolescence (12–18 years; n = 48), and adulthood (>18 years; n = 57); 2) Sex: male (n = 116), female (n = 76), and unknown (n = 2); and 3) Ethnicity: Caucasian (n = 123), African American (n = 29), Hispanic (n = 4), Native American (n = 1), Pacific Islander (n = 1), Asian (n = 1), and unknown (n = 35).

DNA Isolation and Genotype and Copy Number Variation Analyses. Genomic DNA was isolated from liver tissues according to established protocols. Genotyping was performed using PGRN-SeqV1 (Gordon et al., 2016) or the DMET Plus Array, as stated in the manufacturer’s protocol (Affymetrix, Santa Clara, CA). SULT gene copy number variation (CNV) was determined using a quantitative multiplex polymerase chain reaction assay described previously (Gaedigk et al., 2012) for the samples provided by the Children’s Mercy Kansas City.

Protein Extraction, Trypsin Digestion, and Sample Preparation. Human liver cytosol (HLC) fractions were isolated from liver tissues by a differential centrifugation method previously described (Pearce et al., 2016). Total cytosolic protein concentration was determined using the bicinchoninic acid protein assay kit. Three HLC aliquots (approx. 2 mg/ml) were prepared, separately digested, processed, and analyzed by LC-MS/MS by a previously reported protocol (Bhatt et al., 2017), which is detailed in the Supplemental Methodology. Surrogate peptides of SULT proteins were selected according to an optimized approach (Vrana et al., 2017).

LC-MS/MS Instrument and Quantitative Analysis. The LC-MS system consisted of an Acquity UPLC (Waters Technologies, Milford, MA) coupled to Sciex Triple Quadrapole 6500 MS system (Framingham, MA). The mass spectrometer was operated in multiple reaction monitoring mode using positive ion electrospray ionization for targeted peptide analysis. Peak integration and quantification were performed using Skyline software (University of Washington).

The peptides were separated employing Waters Acquity UPLC column (HSS T3, 100 × 2.1 mm, 1.8 μm). The mobile phase was run in a gradient mode, composition of which is described in Supplemental Table 1. Optimized mass instrument parameters for analysis of surrogate peptides of SULTs, along with information on peptide sequences, and their types, are given in Supplemental Table 2. Data analysis utilized a three-step normalization process (Bhatt and Prasad, 2018) to ensure technical robustness. The absolute abundances of SULT1A1 and SULT2A1 were determined with commercially available purified protein standards which were used as calibrators. However, owing to nonavailability of protein standards of SULT1A3 and SULT1B1, their quantification was relative and acquired by normalization to total protein.
Statistical Analysis of LC-MS/MS Proteomics Data. The distribution of age, ethnicity, and sex-dependent protein expression data were subjected to normal distribution tests (Kolmogorov-Smirnov and Shapiro-Wilk) employing GraphPad Prism 5 software (San Diego, CA). Because the data for all studied proteins were not normally distributed, nonparametric tests were applied for the statistical analysis. For age- and genotype-dependent protein abundance data, analyses were performed using the Kruskal-Wallis test followed by Dunn’s multiple comparison test. The effect of sex- and ethnicity-dependent protein abundance was evaluated using the Mann-Whitney rank order U test (using GraphPad Prism software), considering P values of < 0.05 as statistically significant. Jonckheere-Terpstra (JT) test was used for the trend analysis, whereas principal component analysis (PCA) was used to evaluate robustness of sample handling and storage, and also to identify unique patterns in protein abundances, as was done in our earlier studies (Bhatt and Prasad, 2018). Multiple linear regression was performed to rule out confounding effects of multiple covariates (e.g., age vs. ethnicity) during data analysis. Protein-protein correlation of the studied SULT isoforms was analyzed by Spearman correlation. RStudio (version 1.0.136) was used for JT (clinfun package; jonckheere.test function), PCA (prcomp function and ggbiplot package; ggbiplot function), multiple linear regression (lm function), and Spearman correlation (PerformanceAnalytics package; chart.Correlation function) analysis. Wherever applicable, a nonlinear allosteric sigmoidal eq. 1 was used to fit the ontogeny data (Bhatt et al., 2019), as age and enzyme abundance relationship was not expected to be linear.

\[
A = A_{\text{birth}} + \frac{A_{\text{max}} - A_{\text{birth}}}{(\text{Age}_{\text{cell}} + X^h)}
\]

where A is the enzyme abundance at age X; \(A_{\text{birth}}\) is the enzyme abundance at birth; \(A_{\text{max}}\) is the maximum average enzyme abundance; \(\text{Age}_{\text{cell}}\) is the age in years at which 50% enzyme abundance is reached; X is the age in years; and \(h\) is the Hill coefficient.

Acetaminophen PBPK Model Development and Validation in Adults. Acetaminophen PK data in the literature were mostly available either as concentration-time graphs or in the form of tables. The data from plasma concentration-time profiles were extracted with the GetData Graph Digitizer (http://www.getdata-graph-digitizer.com/index.php). Additional information, i.e., route of administration, dose strength, dosing regimen, and demographic details such as age and weight, was also collected. A whole-body PBPK model of acetaminophen for the adult population was developed using GastroPlus v9.6 (Simulations Plus Inc., Lancaster, CA, USA). For the purpose, reported values of adult plasma clearance after intravenous administration (CLIV) and steady-state (\(f_{\text{ss}}\)) values were required to be within 1.25-fold of the observed clinical data; and \(f_{\text{ss}}\) values were calculated as the products of the in vitro \(K_m\) values, which is Michaelis-Menten constant for individual DME isoforms (\(\mu\)M), unbound fraction in microsomes (\(f_{\text{u}}\)) (default GastroPlus value of 1), and in vitro CL\text{int}_{\text{DME}} (microliters per minute per milligram protein) (values in Supplemental Table 3) in accordance with eq. 5.

\[
V_{\text{max, DME}} = \ln \left( \frac{\text{CPPGL}}{C_{\text{PGL}}} \right)
\]

The model was applied to simulate the PK profile of various intravenous dosing regimens of acetaminophen. After validating the disposition model across different clinical data sets, an absorption model was established by integrating oral absorption parameters, such as permeability, solubility, diffusion coefficient, particle size, etc. using “Human-Fasted” gut physiology model of GastroPlus. On the basis of literature, the role of intestinal metabolism of acetaminophen was considered negligible (Clements et al., 1984). Likewise, oral PBPK models of acetaminophen were validated with available clinical data for different dosing regimens, i.e., oral doses of 500–2000 mg.

The predictive performance of the developed models was evaluated by comparing the simulated exposure parameters with literature-based clinical data, in accordance with the criteria suggested in the literature for comparison of area under the plasma concentration-time curve (AUC) and maximum plasma concentration (\(C_{\text{max}}\)) (Abduljalil et al., 2014; Huang et al., 2017). The following criteria were considered: 1) bioequivalence criterion wherein the simulated AUC and \(C_{\text{max}}\) values were required to be within 1.25-fold of the observed clinical data; 2) 2-fold criterion, which allows for a 0.5- to 2-fold variability between simulated and observed data, and 3) population-based criterion, wherein the basis of the fold change boundary is the corresponding observed values. In the latter, acceptance criteria were calculated with consideration of sample size (N) and percent coefficient of variation (%CV) (reported studies lacking N and %CV were excluded). The acceptance ranges of the mean \(C_{\text{max}}\) and AUC were then calculated by eqs. 6–8 (Abduljalil et al., 2014; Huang et al., 2017).

\[
\sigma = \sqrt{\frac{\ln \left( \frac{\text{CV}}{100} \right)^2 + 1}{N}}
\]

\[
A = e^\left( \ln(\alpha) + 4.26 \cdot \frac{\sigma}{\sqrt{N}} \right)
\]

\[
B = e^\left( \ln(\alpha) - 4.26 \cdot \frac{\sigma}{\sqrt{N}} \right)
\]

wherein A and B are the upper and lower boundary limits for simulated data, respectively; \(\alpha\) is the mean of \(C_{\text{max}}\) or AUC of acetaminophen; and \(\sigma\) is the S.D. calculated from the %CV of the Cmax or AUC. Once the PBPK model for acetaminophen was validated, PBPK models for its metabolites were developed using parameters described in Supplemental Tables 4 and 5. Because mechanistic elimination parameters (e.g., active efflux clearance) were not available for the metabolites, we assumed that they were eliminated unchanged in urine and the metabolite kinetics was formation-rate limited.
Accordingly, the predicted total amount of metabolites eliminated in urine ($A_a$) was compared with the observed data.

**Development of Pediatric Acetaminophen PBPK Model.** Following the development of adult acetaminophen PBPK model, we integrated ontogeny data (mean and 95% CI of protein abundance) of SULTs (from this study), UGTs (Bhatt et al., 2019), and CYPs (unpublished data) with pediatric physiologic parameters determined from the PEAR physiology module of GastroPlus software. The intention was to predict acetaminophen PK profile in the pediatric population. Besides major SULTs quantified in this study, published data of SULT1E1 (Duannu et al., 2006) was also used for the model development. The pediatric population models were built for five age groups representing the mean of neonatal (14 days and 3.7 kg body weight), infancy (6 months and 8.23 kg body weight), early childhood (4 years and 17.34 kg body weight), middle childhood (9 years and 34.45 kg body weight), and adolescence (15 years and 63.69 kg body weight). $V_{ss}$ was estimated on the basis of the approach explained in Supplemental Table 3. $f_{up}$ was adjusted by the software to account for both age-related differences in plasma protein level as well as binding to plasma lipids.

Similar protein abundance values were considered for adult and pediatric samples by the software; however, to address the enzyme ontology, we adjusted $V_{max,DEMe}$ (picomoles per minute per milligram protein) values for individual enzymes on the basis of age-dependent protein abundances of SULTs, UGTs, and CYPs (Supplemental Table 3) using eq. 9. Adjusted $V_{max,DEMe}$ values were also used as an input in the Enzymes and Transporter module of GastroPlus.

\[
\text{Adjusted } V_{max, DMe} = \frac{V_{max, DMe}}{SFMPPGL \times C2} \times SFDME \times SFMPPGL \times C2
\]

where, scale factor (SF) was generated for calculating the age-dependent abundances of each DME isomers and MPPGL by eqs. 10 and 11, respectively. The resultant data are listed in Supplemental Table 6.

\[
SF_{DME} = \frac{\text{Mean or 95%CI abundance of DME in pediatric population}}{\text{Mean abundance of DME in healthy adults}}
\]

\[
SF_{MPPGL} = \frac{\text{Mean MPPGL}_{\text{pediatric}}}{\text{Mean MPPGL}_{\text{adult}}}
\]

Thus, age-dependent MPPGL values were integrated for CYPs and UGTs (Calvier et al., 2018). However, the CPPGL value was considered similar for adults and pediatrics as it was observed to be age-independent (unpublished data).

Further, a scaled $CL_{univ, DMe}$ value was obtained through in vitro-in vivo extrapolation with eq. 12.

\[
\text{Scaled } CL_{univ, DMe} = \frac{\text{Adjusted } V_{max, DMe}}{K_{m, DMe} \times f_{unc}} \times \text{MPPGL or CPPGL} \times \text{Liver weight} \times 60 \times 10^{-6}
\]

Default GastroPlus liver weight values for each age group were input in the above-mentioned equation to account for the age-dependent change, viz., neonatal (123.44 g at 14 days), infancy (228.01 g at 6 months), infancy (325.11 g at 1 year), early childhood (592.12 g at 4 years), children (726.23 g at 7 years), middle childhood (906.24 g at 9 years), adolescence (1391.9 g at 14 years), and adolescence (1482.7 g at 15 years).

An age-dependent $f_{unc, DMe}$ value was obtained from the DDI module of GastroPlus as well as from a scaled $CL_{Rut, DMe}$ value as per eq. 13.

\[
f_{unc, DMe} = \frac{\text{Scaled } CL_{Rut, DMe}}{\sum \text{Scaled } CL_{Rut, DMe}} \times (1 - f_{CL, renal})
\]

Since $f_{CL, renal}$ or $f_r$ is age-independent (Miller et al., 1976), the $f_{CL, renal}$ Value was considered to be constant (approx. 0.057) among all the age groups (Supplemental Table 3).

Cumulative $f_{m, SULT}$, $f_{m, UGT}$, and $f_{m, CYP}$ Values were derived from the total of individual isoforms of SULT, UGT, and CYP, respectively, using eq. 14.

\[
f_{m, SULT/UGT/CYP} = \sum f_{m, \text{SULT/UGT/CYP}}
\]

The scaled model was then used to predict acetaminophen PK in children and the predictions were compared with the reported observed data. The model was further extended to predict the dosing regimen in neonates and infants, which was validated by comparison with the dose adjustments recommended by the United States Food and Drug Administration (USFDA). Evaluation of the pediatric model was done by application of the same approach as discussed for the adult model. Also similar to the adults, prediction of $A_a$ of the metabolites and unchanged drug was made for the pediatric groups.

**Results**

**Abundances and Variability of Human SULT Enzymes.** The mean cytosolic protein abundances of SULT1A1, SULT1A3, SULT1B1, and SULT2A1 in the neonates (0–27 days) were 24%, 47%, 19%, and 38%, respectively, of the mean values for the adults (>18 years) (Fig. 1; Table 1). In the infants (28–364 days), the values for these SULT isoforms were 80%, 76%, 41%, and 111% of the adult levels, respectively. SULT1A1 protein abundance in early childhood (1 to <6 years) was approx. 7-fold higher compared with the neonatal and approx. 2-fold higher than the adults. The association of categorical SULT1A3 abundance data with age was not significant (Fig. 1). SULT1B1 protein abundance in the adults was found to be approx. 5.4- and 2.4-fold higher than in the neonates ($P < 0.05$) and the infants ($P < 0.0001$), respectively. Likewise, SULT2A1 protein abundance in early childhood was approx. 4- and 2-fold higher compared with the neonatal and adolescence (12–18 years), respectively.

The developmental trajectory of each SULT isoform was also assessed using age as a continuous variable (Supplemental Fig. 1). Data for both SULT1A3 and SULT1B1 could be adequately characterized by a nonlinear allosteric sigmoidal model justified by the fact that the age and enzyme-abundance relationship was not linear. The latter is consistent with the literature regarding ontogeny of DMEs (Johnson et al., 2006; Upreti and Wahlstrom, 2016; Boberg et al., 2017; Emoto et al., 2018). In both cases, the age$_{50}$ value (the age at which protein expression reached 50% of the maximum adult abundance) was determined to be 0.91 years, i.e., approx. 11 months (Supplemental Fig. 1; Supplemental Table 7). The high biologic variability in SULT1A3 and SULT1B1 resulted in poor confidence in the age$_{50}$ calculation, yet age-dependent abundances of these enzymes was supported by other statistical methods (Kruskal-Wallis test, multiple linear regression analysis, and JT trend analysis). However, this ontology model and statistical tests were not appropriate for SULT1A1 and SULT2A1 data, in which the developmental trajectories were characterized by protein abundance reaching maximum values in the toddler/early childhood group, and subsequently declining to the adult values.

**Association of Ethnicity, Single-Nucleotide Polymorphisms, Copy Number Variations, and Sex with SULT Abundance.** The protein abundances of SULT1A3 and SULT1B1 was significantly higher in Caucasians compared with African Americans ($P < 0.0001$) (Fig. 2; Table 1). But an age-ethnicity interplay made it difficult to draw a precise conclusion in the first instance. Therefore, multiple linear regression analysis, and JT trend analysis. However, this ontology model and statistical tests were not appropriate for SULT1A1 and SULT2A1 data, in which the developmental trajectories were characterized by protein abundance reaching maximum values in the toddler/early childhood group, and subsequently declining to the adult values.
relationship with ethnicity and sex in this case. The Mann-Whitney test indicated no association of ethnicity and SULT2A1 abundance, perhaps because of age-related variability. On the other hand, multiple linear regression analysis concluded that ethnicity was one of the key variables in the abundance of SULT2A1. Interestingly, the multiple linear regression analysis showed a modest, but significantly higher abundance of SULT2A1 in females than in males ($P$ value, 0.05). No significant association of protein abundance was observed for other high-frequency SNPs, i.e., rs982861 (SULT1A1); rs11569731, rs11731028, rs11731028, rs1604741 (SULT1B1); and rs296365 (SULT2A1). The statistical results for this portion are summarized in Supplemental Figs. 4 and 5 and Supplemental Tables 8 and 9.

**Protein-Protein Correlation.** This study, which was done with an objective to look for coregulation of SULT proteins, highlighted strong correlation between abundance levels of SULT1A1 and SULT2A1 ($r^2$ = 0.60, $P$ value < 0.001; Supplemental Fig. 6). Likewise, SULT1A3 showed correlation with SULT1B1 ($r^2$ = 0.61 and $P$ value < 0.05).

**PCA Analysis of Proteomics Data.** The PCA analysis, which was done to evaluate robustness of sample handling and storage, and to identify unique patterns in protein abundances, highlighted that there was no degradation of samples before and during processing. As shown in our previous report (Bhatt and Prasad, 2018), data for degraded samples clustered distinctly toward the left lower side of PC1 vs. PC2 plots. In the present case, there was no clustering in the indicated region.
and 95% CI data of protein abundance. As shown in Figs. 3 and 4, the adults.

Regarding identification of unique patterns, the circled areas in the PCA plot (Supplemental Fig. 7) confirmed higher variability in the pediatric groups (0–18 years) for all SULT enzymes, compared with the adults.

**Prediction of Age-Dependent Fractional Contribution of Sulforaphane in Acetaminophen Metabolism.** Considering that demonstration of the application of the ontogeny data was a key objective of this study, other population covariates were not considered for overall interindividual variability prediction (%CV), meaning that the predictions were made solely on the basis of mean and 95% CI data of protein abundance. As shown in Figs. 3 and 4 and Table 2, the observed versus predicted AUC and Cₘₐₓ values of acetaminophen for both intravenous and oral administration in fasted- and fed-states were within the acceptance criteria. It is clearly evident from the data in Table 2 that 2-fold and population-based criteria yielded higher numbers of results within acceptable limits than the bioequivalence criterion. This confirmed that the latter was stringent in comparison, a reason why it is rarely used in PBPK modeling. Hence, our results relied only on 2-fold and population-based criteria. As 2-fold criterion is most commonly used for PBPK model validation, it was considered as the reference criterion for model acceptance in this study. But as it is also an arbitrary method and does not consider biologic variability in the data, additional analysis of predictive performance of the PBPK model was done using the population-based criterion.
The validated adult PBPK model was employed for prediction of PK in the pediatric population because it considered all the relevant information gathered. There was under-prediction of acetaminophen AUC for the pediatric population when DME ontogeny data were not considered (Fig. 4). The \( \text{fm, ratio} \) values (e.g., \( \text{fm, UGT}/\text{fm, SULT} \)) predicted by the ontogeny-based model were 0.46, 0.56, and 1.71 in neonates, children, and adults, respectively (Fig. 5; Table 3). These predicted \( \text{fm} \) and corresponding \( \text{Ae} \) data were in agreement with those observed (Fig. 5). Data in Supplemental Table 10 show that model-predicted pediatric PK data even correlated well with the FDA-recommended dose adjustments.

**Discussion**

Some data exist in the literature regarding the ontogeny of SULT1A1, SULT1A3, SULT2A1, and SULT1E1 (Brashear et al., 1988; Barker et al., 1994; Richard et al., 2001; Behm et al., 2003; Pacifici, 2005; Stanley et al., 2005; Duanmu et al., 2006; Ekström and Rane, 2015). However, several limitations are associated with these studies, for example: 1) lack of specific antibodies for the Western blotting, 2) use of nonselective in vitro or in vivo probe substrates for the activity, 3) smaller numbers of samples, and 4) inconsistent mRNA data that show poor correlation with functional activity. Hence, a comprehensive investigation of the ontogeny of SULT enzymes using an LC-MS/MS proteomics approach was performed in this study.

Among the notable findings, we observed that the ontogeny of hepatic SULTs are opposite to the trend of ontogeny of UGTs and most CYPs that are poorly expressed in fetal and early neonatal ages but are abundant in adult (Pacifici et al., 1982, 1993; Choonara et al., 1989; McCarver and Hines, 2002; Hines, 2007; Upreti and Wahlstrom, 2016). Using the same donor samples, we recently reported that, compared with adults, UGT levels were 3%–40% in the neonates, 24%–60% in the infants, and 37%–72% in the childhood age (Bhatt et al., 2019). These data are consistent with the literature, in which adult to fetal ratios of UGT and SULT activities are shown to be 114 and 3.5, respectively (Pacifici et al., 1989). Likewise, SULT1A3-mediated dopamine sulfation activity is shown to be 3-fold higher in the fetal liver compared with the adult liver, whereas an opposite trend was observed in SULT1A1 4-nitrophenol sulfation activity (Cappiello et al., 1991). Ritodrine, a tocolytic agent for the management of preterm labor, is inactivated by sulfation and glucuronidation. The ratio of ritodrine sulfate to glucuronide in urine was found to be higher in newborns, whereas the ratio was equal in maternal urine (Brashear et al., 1988; Pacifici et al., 1993). Such observed differential DME ontogeny has a direct significance in vivo for drugs metabolized by multiple DMEs (e.g., SULTs, UGTs, CYPs, etc.).

Our data do not agree with other reports in a few instances. For example, we observed that SULTs (particularly SULT1A1 and SULT2A1) are expressed at higher levels in childhood age (1–12 years) compared with the adolescents and adults. This is not in agreement with the observations by Duanmu et al. (2006), who found no difference in hepatic SULT1A1 and SULT2A1 abundances in postnatal samples. A limited number of pediatric samples from children between 2 and 10 years could be a potential reason for this discrepancy. Likewise,
Although SULT1A3 was detected in all age groups in our study, this enzyme was only detected in fetal and neonatal livers by others (Richard et al., 2001). We believe this indicates a better sensitivity of our method. Further, LC-MS/MS proteomics allowed discrimination of the highly homologous SULT proteins compared with conventional antibody- or activity-based methods.

Practically nothing was known previously regarding SULT1B1 ontogeny. Our data show a significant and gradual age-dependent increase in SULT1B1 abundance during the first year of life, unlike SULT1A1 and SULT2A1 enzymes, but similar to CYPs and UGTs. The mechanisms that regulate the age-dependent abundances of SULTs remain unclear. However, transcription and environmental factors could be the potential regulators of SULT expression during development. The differential tissue and cross-species expression are considered to be regulated by aryl hydrocarbon receptor, constitutive androstane receptor, pregnane X receptor (PXR), liver X receptor, farnesoid X receptor (FXR), peroxisome proliferator-activated receptors (PPARs), and vitamin D receptor (Dubaisi et al., 2018). As the expression of some of these transcriptional factors, e.g., PXR, PPARα, or PPARγ, is age-dependent (Balasubramaniyan et al., 2005), one can anticipate their role in corresponding developmental change in SULT abundance. In particular, the expression of SULT2A1 is reported to increase 2-fold in fetal hepatocyte culture by agonists of PPARα (GW7647) or PPARγ (rosiglitazone) and suppressed by the FXR agonist (GW4064) (Dubaisi et al., 2018). Steroidogenic factor 1 and GATA-binding factor 6 are also reported to be involved in regulation of SULT2A1 in the adrenals (Saner et al., 2005). Likewise, because SULT2A1 is the major DHEA-metabolizing enzyme and the levels of urinary DHEA and hydroxylated DHEA (representing sulfate conjugates) transform during early to late childhood age, one can postulate that DHEA is involved in the regulation of SULT2A1 during the pubertal development (Rainey et al., 2002; Remer et al., 2005). This is also

---

Fig. 3. Observed vs. predicted dose-normalized acetaminophen plasma concentration-time profiles for: intravenous infusion (2 hours) (A), oral solution-fasted state (B), oral tablet-fasted state (C), and oral tablet-fed state (D) dosing in adults. These profiles were generated by dividing the observed or predicted plasma concentrations by the dose. The gastric emptying time considered for the fed-state was 1 hour, whereas for the fasted state, oral tablet and oral solution, it was considered to be 15 and 6 minutes, respectively. The symbols represent observed data, and the solid lines indicate the model-predicted mean profile. The dotted and dashed lines represent the predicted profiles when lower and higher 95% CI of protein abundances of UGTs, SULTs, and CYPs (age ≥18 years) were considered for metabolism-related interindividual variability in adults. Abbreviations used in the illustration represent the following: L1 (5 mg/kg, predicted-fasted state); L2 [5 mg/kg (Clements et al., 1984)]; L3 [20 mg/kg (Clements et al., 1984)]; L4 (1000 mg, predicted-fasted state); L5 [1000 mg (Kamali et al., 1992)]; L6 (1000 mg (Prescott et al., 1989)); L7 [12 mg/kg (Prescott, 1980)]; L8 (5 mg/kg, predicted-fasted state); L9 [500 mg (Rawlins et al., 1977)]; L10 [1000 mg (Rawlins et al., 1977)]; L11 [2000 mg (Rawlins et al., 1977)]; L12 [1000 mg (Singla et al., 2012)]; L13 [1000 mg (Zapater et al., 2004)]; L14 [1000 mg (Rostami-Hodjegan et al., 2002)]; L15 (1000 mg, predicted-fed state), and L16 [1000 mg (Rostami-Hodjegan et al., 2002)].
supported by the fact that adrenal expression of SULT2A1 increases with the gradual growth of adrenal zona reticularis (Nakamura et al., 2009).

In accordance with our objective, we applied the differential ontogeny data of SULTs, UGTs, and CYPs to estimate the effect of age on \( f_m \) values of these enzymes in acetaminophen metabolism. The major reason to select this drug was the availability of extensive reported in vitro and PK data in the neonates, infants, and children (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000ClinPharmR.pdf; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/204767Orig1s000TOC.cfm). The predicted \( f_m \) and corresponding metabolite \( A_e \) data were in good agreement with the observed data (Fig. 5). For example, the ratio of UGT/SULT \( f_m \) for acetaminophen was simulated to be 0.46, 0.56, and 1.71 compared with the observed values of the excreted fraction of glucuronide/sulfate metabolite of 0.34, 0.75, and 1.8 in the neonates, children, and adults, respectively (Miller et al., 1976). Acetaminophen is also transformed to \( N \)-acetyl-\( p \)-benzoquinone imine (NAPQI), an hepatotoxic metabolite mainly formed through oxidative mechanism via CYP2E1. Accurate \( f_m \) prediction for CYP-mediated bioactivation of acetaminophen is important for predicting toxicity in children. With higher contribution of SULT in the clearance of various drugs in children, including acetaminophen, it is hypothesized that SULT-mediated DDIs or food-drug interactions may be significant in the pediatric population.

Our proteomics-informed PBPK predictions of acetaminophen PK in neonates and infants are consistent with the FDA label doses for acetaminophen injection. For example, FDA suggests a dose reduction of 50% and 33% for the neonates and infants, respectively, to produce PK exposure similar to that of children. The origin of this dose reduction is related to age-dependent in vivo clearance of the drug (Zuppa et al., 2011). The extent of acetaminophen dose reduction in pediatrics is reasonably captured by our model (Supplemental Table 10).

No significant association of ethnicity has been previously reported for sulfation clearance of acetaminophen in adults (African Americans and European Americans) (Court et al., 2017). Rather, we found that SULT1A3 and SULT1B1 abundances were significantly lower in African Americans compared with Caucasians, which represented a majority of pediatric samples. Although the mechanisms leading to these differences are unknown, genetic polymorphisms or environmental factors could be tested in the future as potential contributors.

No association of sex with enzyme abundances was observed across all age groups and ethnicity for SULT1A1, SULT1A3, and SULT1B1,

---

Fig. 4. Observed vs. predicted plasma concentration-time profiles of acetaminophen in neonates and infants for the mentioned doses. The drug was delivered as an intravenous infusion for 15 minutes in the case of all the figures (A, B, and D-F), except (C) in which the duration of infusion was 50 minutes. Also, separately indicated as bar diagrams is the comparison of mean predicted (without and with proteomics-based ontogeny data) and observed (L20) \( C_{\text{max}} \) (G), and \( \text{AUC}_{0-6} \) (H) values for 15 mg/kg acetaminophen administered as intravenous infusion for 15 minutes to neonates and infants. In this case, the average age values for neonates and infants were considered as 14 days and 1 year, respectively, in accordance with US-FDA label (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000ClinPharmR.pdf). Abbreviations used in the illustration represent the following literature references: L17 (Zuppa et al., 2011), L18 (Cook et al., 2016), L19 (Allegaert et al., 2013), and L20 (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000ClinPharmR.pdf).
TABLE 2
Comparison of acetaminophen PBPK model predicted and observed PK data

Clinical studies were used as the training and validation sets. The observed and the predicted Cmax (µg/ml) and AUC (µg h/ml) (mean, lower and higher 95% CI of the proteomics data of DMEs) for these studies are shown for all pediatric and adult populations and for the intravenous and oral routes of administration. The simulated mean Cmax (µg/ml) and AUC (µg h/ml) values were compared with the observed data and the acceptance criteria [on the basis of bioequivalence criterion (1.25-fold), 2-fold criterion, and population-based criterion] was determined. Study ID in the table represent the following: 1 (Clements et al., 1984); 2 (Singla et al., 2012); 3 (Bussell et al., 1979); 4 (Perucca and Richards, 1979); 5 (Prescott, 1980); 6 (Zapater et al., 2004); 7 (Rostami-Hodjegan et al., 2002); 8 (Manyike et al., 2000); 9 (Kamali et al., 1992); 10 (Prescott, 1980); 11 (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022450Orig1s000ClinPharmR.pdf), and 12 (Rømsing et al., 2001).

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Dose Parameters</th>
<th>Mean Observed Value (O)</th>
<th>Acceptance Range</th>
<th>Mean Predicted Value (P)</th>
<th>P/O Ratio</th>
<th>Compliance to Model Evaluation Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Compliance to Model Evaluation Criteria</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bioequivalence criterion</td>
</tr>
<tr>
<td>Intravenous (adults)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>5 mg/kg AUC (0–inf, h)</td>
<td>18.38</td>
<td>15.50–21.80</td>
<td>18.42</td>
<td>1.00</td>
<td>Yes</td>
</tr>
<tr>
<td>2</td>
<td>1000 mg Cmax (0–inf, h)</td>
<td>21.6</td>
<td>15.86–29.42</td>
<td>30.01</td>
<td>1.39</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>1000 mg AUC (0–inf, h)</td>
<td>42.5</td>
<td>31.96–46.52</td>
<td>42.22</td>
<td>0.99</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>1000 mg Cmax (0–inf, h)</td>
<td>50.5</td>
<td>31.50–80.96</td>
<td>53.42</td>
<td>1.06</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>12 mg/kg AUC (0–inf, h)</td>
<td>36.7</td>
<td>34.23–39.35</td>
<td>44.99</td>
<td>0.81</td>
<td>No</td>
</tr>
<tr>
<td>Oral tablet (adults)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>1000 mg Cmax</td>
<td>12.3</td>
<td>6.14–24.63</td>
<td>11.15</td>
<td>0.91</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>1000 mg AUC (0–inf, h)</td>
<td>42.5</td>
<td>31.96–56.52</td>
<td>42.22</td>
<td>0.99</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>1000 mg Cmax</td>
<td>50.5</td>
<td>31.50–80.96</td>
<td>53.42</td>
<td>1.06</td>
<td>Yes</td>
</tr>
<tr>
<td>5</td>
<td>1000 mg AUC (0–inf, h)</td>
<td>44.0</td>
<td>30.87–64.89</td>
<td>44.99</td>
<td>0.81</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>1000 mg AUC (0–6 h)</td>
<td>67.6</td>
<td>53.42–90.68</td>
<td>70.00</td>
<td>1.10</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>1000 mg AUC (0–inf, h)</td>
<td>57.4</td>
<td>45.35–86.67</td>
<td>60.00</td>
<td>1.05</td>
<td>Yes</td>
</tr>
<tr>
<td>8</td>
<td>500 mg Cmax</td>
<td>6.5</td>
<td>3.85–10.10</td>
<td>7.47</td>
<td>0.68</td>
<td>No</td>
</tr>
<tr>
<td>9</td>
<td>1000 mg AUC (0–inf, h)</td>
<td>44.0</td>
<td>30.87–64.89</td>
<td>44.99</td>
<td>0.81</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>12 mg/kg AUC (0–inf, h)</td>
<td>28.3</td>
<td>19.09–39.33</td>
<td>30.01</td>
<td>1.39</td>
<td>Yes</td>
</tr>
<tr>
<td>Intravenous (neonates)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>15 mg/kg Cmax (0–inf, h)</td>
<td>25.4</td>
<td>18.88–37.35</td>
<td>27.78</td>
<td>1.10</td>
<td>Yes</td>
</tr>
<tr>
<td>12</td>
<td>Intravenous (infants)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>15 mg/kg AUC (0–inf, h)</td>
<td>32.8</td>
<td>24.73–44.02</td>
<td>37.33</td>
<td>1.25</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>Intravenous (children)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>15 mg/kg Cmax (0–inf, h)</td>
<td>29.9</td>
<td>21.32–36.07</td>
<td>30.01</td>
<td>1.00</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>Intravenous (adolescents)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>15 mg/kg Cmax (0–inf, h)</td>
<td>38.3</td>
<td>30.68–44.02</td>
<td>47.33</td>
<td>1.25</td>
<td>Yes</td>
</tr>
<tr>
<td>11</td>
<td>Intravenous (middle childhood)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>22.5 mg/kg AUC (0–inf, h)</td>
<td>12.7</td>
<td>8.56–18.84</td>
<td>13.70</td>
<td>0.78</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Fig. 5. Ontogeny-based predicted fm values of acetaminophen-metabolizing enzymes across different age-groups (neonatal to adulthood) after oral administration of 10 mg/kg drug solution, as estimated in this study (shown by pie charts A–F). The pie charts are shown in different diameters to represent the magnitude of apparent clearance (CL/F = Dose/AUC0–inf). The predicted fm values were further confirmed by comparison of observed and predicted urinary recoveries (Ae, mmol) of acetaminophen (APAP), acetaminophen-sulfate (APAP-S), and acetaminophen-glucuronide (APAP-G) across different age-groups (shown as bar diagrams G–L). The predicted Ae data were generated in respective age groups after consideration of mean (bar) and 95% CI (error bars) protein abundance data. Dots indicate observed urinary elimination data. Abbreviations used in the illustration represent the following: L21 (Miller et al., 1976); L22 (Alam et al., 1977); L23 (Clements et al., 1984); L24 (Critchley et al., 1986), and L25 (Critchley et al., 2005).
Age-dependent abundances of SULTs and its implications

TABLE 3
Ontogeny-based predicted UGT/SULT \( f_a \) values of acetaminophen across different age groups.

<table>
<thead>
<tr>
<th>Age Groups (Mean, Range)</th>
<th>UGT/SULT ( f_a )</th>
<th>Mean</th>
<th>Lower 95% CI</th>
<th>Higher 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neonatal (14 day, 0–27 day)</td>
<td>0.46</td>
<td>0.12</td>
<td>0.55</td>
<td></td>
</tr>
<tr>
<td>Infancy (6 mo, 28–364 day)</td>
<td>0.54</td>
<td>0.62</td>
<td>0.50</td>
<td></td>
</tr>
<tr>
<td>Infancy (1 yr, 29 &lt; &lt;6 yr)</td>
<td>0.44</td>
<td>0.49</td>
<td>0.42</td>
<td></td>
</tr>
<tr>
<td>Toddler/early childhood (4 yr, 1 &lt; &lt;6 yr)</td>
<td>0.47</td>
<td>0.45</td>
<td>0.48</td>
<td></td>
</tr>
<tr>
<td>Middle childhood (9 yr, 6 &lt; &lt;12 yr)</td>
<td>0.64</td>
<td>0.62</td>
<td>0.64</td>
<td></td>
</tr>
<tr>
<td>Children (7 yr, 2 &lt; &lt;12 yr)</td>
<td>0.56</td>
<td>0.56</td>
<td>0.56</td>
<td></td>
</tr>
<tr>
<td>Adolescence (14 yr, 12–16 yr)</td>
<td>1.02</td>
<td>1.18</td>
<td>0.91</td>
<td></td>
</tr>
<tr>
<td>Adolescence (15 yr, 12–18 yr)</td>
<td>0.97</td>
<td>1.08</td>
<td>0.90</td>
<td></td>
</tr>
<tr>
<td>Adult hood (30 yr, &gt; 18 yr)</td>
<td>1.71</td>
<td>1.60</td>
<td>1.86</td>
<td></td>
</tr>
</tbody>
</table>

95% CI: 95% confidence interval.

albeit multiple linear regression analysis showed a modest, but significantly higher abundance of SULT2A1 in females consistent with reported mouse data (Kocarek et al., 2008) and perhaps owing to the role of SULT2A1 in androgen disposition.

Drugs such as clomiphene, danazol, imipramine, chlorpheniramine, spironolactone, chlorpromazine, amitriptyline, and propranolol are potent inhibitors of SULT enzymes (Coughtrie et al., 1994; Marto et al., 2017) and can produce greater DDIs with SULT substrates in children. A risk of SULT-mediated drug-food interactions also exists in children (Nishimuta et al., 2007), as constituents of certain beverages can inhibit SULT enzymes. Various endogenous molecules, such as bile acid, estrogen, thyroid hormones, catecholamines, DHEA, etc., can be differentially affected by modulators of SULT activity, depending on age (Coughtrie et al., 1994; Coughtrie, 2002). The ontogeny data of SULTs presented here can prove useful in interpreting these data.

Regarding limitations of this study, we were unable to quantify SULT1E1 owing to a higher limit of quantification of its surrogate peptide. Further, data for SULT2A1 CNV and SNPs including rs296361, which have previously been shown to affect protein abundance level to determine interindividual variability in DMET proteins by LC-MS/MS. Further, the PBPK model accurately predicted AUC as well as \( f_a \) for in vivo observations. Drug Metab Dispos 42:1478-1484.


Bobberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, Leeder JS, and Prasad B (2017) Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by

References


Bobberg M, Vrana M, Mehrotra A, Pearce RE, Gaedigk A, Bhatt DK, Leeder JS, and Prasad B (2017) Age-dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by


Address correspondence to: Dr. Bhagwat Prasad, Department of Pharmaceutics, University of Washington, Seattle, WA 98195. E-mail: bhagwat@uw.edu; or Dr. Saranjit Singh, Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Mohali (S.A.S. Nagar) 160062, Punjab, India. E-mail: sssingh@niper.ac.in